CARMIEL, Israel, Oct. 19, 2015 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE MKT: PLX ) PLX, announced today positive long term data from the 0.2mg, or lowest dose, of the Company's phase I/II dose ranging clinical trial of PRX-102 for the treatment of Fabry disease. PRX-102 is a recombinant plant cell expressed, chemically modified version of the human alpha-Galactosidase-A enzyme.